+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Amgen Inc. - logo

Amgen is an international biotechnology company based in California, USA. Amgen is committed to using their experience in human genetics and biologics manufacturing to create innovative treatments for life threatening diseases particularly in areas of unmet medical need where limited treatment options exist. Amgen manufactures a wide range of therapeutic products including Aranesp, Corlanor, Neulasta and Prolia.

Secondary Hyperparathyroidism - Pipeline Insight, 2024 - Product Thumbnail Image

Secondary Hyperparathyroidism - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Pediatric Drugs and Vaccines - Global Strategic Business Report - Product Thumbnail Image

Pediatric Drugs and Vaccines - Global Strategic Business Report

  • Report
  • November 2024
  • 292 Pages
  • Global
From
Biosimilars World Market - Product Thumbnail Image

Biosimilars World Market

  • Report
  • January 2023
  • 28 Pages
  • Global
From
From
From
From
Chemotherapy-induced thrombocytopenia (CIT) - Pipeline Insight, 2024 - Product Thumbnail Image

Chemotherapy-induced thrombocytopenia (CIT) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Postmenopausal Osteoporosis Treatment Global Market Report 2024 - Product Thumbnail Image

Postmenopausal Osteoporosis Treatment Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
From
Neutropenia Biologic Drug Treatment Global Market Report 2024 - Product Thumbnail Image

Neutropenia Biologic Drug Treatment Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
Targeted Oncology Therapeutics: Lung Cancers - Product Thumbnail Image

Targeted Oncology Therapeutics: Lung Cancers

  • Report
  • October 2021
  • 82 Pages
  • Global
From
Biosimilars Market 2024-2028 - Product Thumbnail Image

Biosimilars Market 2024-2028

  • Report
  • August 2024
  • 180 Pages
  • Global
From
From
Rituximab-Biosimilars Insight, 2022 - Product Thumbnail Image

Rituximab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 125 Pages
  • Global
From
Loading Indicator